KURA ONCOLOGY, INC.

(KURA)
  Report
Real-time Estimate Cboe BZX  -  02:34 2022-07-06 pm EDT
19.18 USD   -1.39%
06/23KURA ONCOLOGY, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/26Kura Oncology to Participate in Three Upcoming Investor Conferences
AQ
05/04KURA ONCOLOGY : Q1 Earnings Snapshot
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Kura Oncology, Inc.
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company’s segment is engaged in discovery and development of medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. It is developing its product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and hematologic indications. It is developing KO-539, a small molecule inhibitor of the Lysine K-specific Methyltransferase 2A (KMT2A) interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The Company is developing orally available, small molecule compounds that inhibit the interaction between the proteins menin and MLL for the treatment of MLL-rearranged (MML-r) leukemias, a genetically-defined subset of approximately two forms of acute leukemia, acute myeloid leukemia (AML) and acute lymphoblastic.

Number of employees : 121 people.
Managers
Name Title Age Since
Troy E. Wilson, Dr. Chairman, President, CEO & Chief Financial Officer 52 2022
Mollie Leoni Senior Vice President-Clinical Development - 2022
Stephen Dale Chief Medical Officer 49 2020
Kathleen Ford Chief Operating Officer 74 2019
Pete de Spain SVP-Investor Relations & Corporate Communications - 2022
Teresa Bair Secretary & Chief Legal Officer 50 2021
Blake Tomkinson, Dr. Head-Portfolio Strategy & Program Management - -
Kirsten Flowers Chief Commercial Officer 46 2020
Nic G. Scalfarotto, Dr. Senior Vice President-Regulatory Affairs - -
Thomas Doyle Chief Accounting Officer & Senior VP-Finance 50 2022
Members of the board
Name Title Age Since
Troy E. Wilson, Dr. Chairman, President, CEO & Chief Financial Officer 52 2022
Faheem Hasnain Lead Independent Director 62 2020
Thomas R. Malley Independent Director 52 2015
Steven Stein Independent Director 54 2017
Mary T. Szela Independent Director 57 2018
Diane L. Parks Independent Director 68 2019
Carol Anne Schafer Independent Director 57 2021
Helen Collins, Dr. Independent Director 59 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 66,636,105 62,935,995 94.4% 0 0.0% 94.4%
Shareholders
NameEquities%
Ecor1 Capital LLC 6,638,371 9.96%
Avoro Capital Advisor LLC 4,800,000 7.20%
Deerfield Management Company LP 4,416,361 6.63%
Suvretta Capital Management LLC 3,893,019 5.84%
Deep Track Capital LP 3,412,000 5.12%
SSgA Funds Management, Inc. 3,300,748 4.95%
The Vanguard Group, Inc. 3,266,403 4.90%
Holocene Advisors, LP 3,242,808 4.87%
BVF Partners LP 3,203,783 4.81%
Eventide Asset Management LLC 2,061,044 3.09%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Kura Oncology, Inc.